AbCellera Biologics Inc. ABCL

Company Overview

AbCellera Biologics Inc. is a Canadian biotechnology company focused on the discovery and development of antibody-based medicines. The company operates at the intersection of biotechnology, artificial intelligence, data science, microfluidics, and high-throughput screening to identify therapeutic antibodies for pharmaceutical and biotechnology partners. AbCellera’s business model is centered on providing antibody discovery capabilities through research collaborations, licensing arrangements, and downstream economic participation in partnered drug programs, including milestone payments and royalties.

The company’s primary revenue drivers include research fees from collaboration agreements, milestone payments tied to clinical and regulatory progress, and royalty interests in commercialized therapeutics. AbCellera serves large pharmaceutical companies, emerging biotechnology firms, and government-related research initiatives. The company gained broad industry recognition through its collaboration with Eli Lilly during the COVID-19 pandemic, which led to the rapid discovery of bamlanivimab. Founded in 2012 by Carl Hansen and colleagues as a spinout from the University of British Columbia, AbCellera evolved from an academic antibody discovery platform into a publicly traded biotechnology company listed on Nasdaq under the ticker ABCL.